Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

6612.00 -19.50 (-0.29%)

New 52W High in past week

805.1K NSE+BSE Volume

NSE 30 May, 2025 3:31 PM (IST)

1

Broker 1Year buys

1 active buys

1

Broker 1Year sells

1 active sells

6

Broker 1Year neutral

6 active holds

Divi's Laboratories Ltd. share price target

Divi's Laboratories Ltd. has an average share price target of 5900.88. The consensus estimate represents a downside of -10.75% from the last price of 6612. View 12 reports from 8 analysts offering long-term price targets for Divi's Laboratories Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	31 May 2025	Divi's Laboratories	Consensus Share Price Target	6612.00	6364.73	-	-3.74	hold	pdf Detailed Estimates
	10 Feb 2024	Divi's Laboratories	BOB Capital Markets Ltd. Reco Target	6612.00	3000.00	3652.30 (81.04%)		Sell	pdf post cache		Broker Report Divi's Labs (SELL): Healthy margin recovery, heady valuations BOB Capital Markets Ltd. Q3 revenue grew 9% YoY on 25% rise in custom synthesis business; API and nutraceuticals stayed soft pdf Copy Link Share on Share on Share on Share on Alert
	09 Nov 2023	Divi's Laboratories	Geojit BNP Paribas Reco Target	6612.00	3800.00	3498.50 (89.00%)	Target met	Hold	pdf post cache		Broker Report DIVI' S LAB Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2023	Divi's Laboratories	SMC online	6612.00		3481.40 (89.92%)		Results Update	pdf post cache		Broker Report Divis Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	06 Nov 2023	Divi's Laboratories	Motilal Oswal Target	6612.00	3330.00	3506.70 (88.55%)	Target met	Neutral	pdf post cache		Broker Report Pricing pressure in API segment hurts profitability Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	15 Aug 2023	Divi's Laboratories	ICICI Securities Limited Target	6612.00	3680.00	3730.55 (77.24%)	Target met	Hold	pdf post cache		Broker Report Margins at inflection, outlook improving ICICI Securities Limited Divi’s Laboratories’ (Divi’s) Q1FY24 revenue growth was impacted by severe pricing pressure in Europe though EBITDA margin at 28.3% was broadly in line with the guidance of a sequential recovery. Raw material cost (down 373bps QoQ) has also started softening now. pdf Copy Link Share on Share on Share on Share on Alert
	15 Aug 2023	Divi's Laboratories	Prabhudas Lilladhar Reco Target	6612.00	3000.00	3730.55 (77.24%)		Sell	pdf post cache		Broker Report DIVI'S LABORATORIES Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	15 Aug 2023	Divi's Laboratories	Motilal Oswal Target	6612.00	3430.00	3730.55 (77.24%)	Target met	Neutral	pdf post cache		Broker Report Margin recovers; sales yet to pick up Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	24 May 2023	Divi's Laboratories	Geojit BNP Paribas Target	6612.00	3783.00	3383.15 (95.44%)	Target met	Buy	pdf post cache		Broker Report DIVI' S LAB Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2023	Divi's Laboratories	SMC online	6612.00		3385.80 (95.29%)		Results Update	pdf post cache		Broker Report Divis Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	22 May 2023	Divi's Laboratories	ICICI Securities Limited Target	6612.00	3560.00	3265.00 (102.51%)	Target met	Accumulate	pdf post cache		Broker Report Pricey RM dampens margins; outlook improving ICICI Securities Limited Divi’s Laboratories’ (Divi’s) has posted its highest ever quarterly sales in generics segment of Rs10bn, up 42% YoY in Q4FY23, though a surge in raw material price and overhead cost has impacted margins (down 1,670bps YoY). Management has indicated a gradual improvement in margins Q1FY24 onwards as it has exhausted high-priced inventory and raw material prices are also declining. pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners